A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Active, not recruiting · Phase 2 · NCT03888105
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 515
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Odronextamab (drug)
- Dates
- Started 2019-11-13; completion 2028-12-15
- Results posted
- Not yet
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works in the body * How much odronextamab is present in the blood
From ClinicalTrials.gov, last updated 2026-07-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $1.7M in research payments for this study in 2025 (303 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Umar Farooq, MD Hematology & Oncology · Iowa City, IA
- Parameswaren Venugopal, M.D. Hematology · Chicago, IL
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Deepa Jagadeesh, M.D. Internal Medicine · Worcester, MA
- Andreas K. Klein, MD Hematology & Oncology · Boston, MA
- Jose C. Villasboas Bisneto, M.D. Hematology · Rochester, MN
- Rakhee R. Vaidya, MBBS Hematology & Oncology · Winston Salem, NC
- Lori A. Leslie, M.D. Medical Oncology · Hackensack, NJ
- John N. Allan, M.D. Hematology & Oncology · New York, NY
- Jon E. Arnason, MD Internal Medicine · New York, NY
- Thomas Jandl, M.D. Hematology & Oncology · Stony Brook, NY
- Farrukh T. Awan, M.D., M.S. Hematology & Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell University $570,633
- $323,223
- Cleveland Clinic, OH $203,479
- Wake Forest University Health Sciences $160,310
- The University of Texas Southwestern Medical Center $107,926
- Beth Israel Deaconess Medical Center, MA $85,313
- Norton Hospitals, Inc, KY $78,675
- Tufts Medical Center, MA $71,665
- University of Iowa Hospital & Clinics, IA $65,217
- Hackensack University Medical Center, NJ $28,635
- Rush University Medical Center, IL $22,302
- Mayo Clinic $16,500
- The Research Foundation for The State University of New York $13,531
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.